TAIPEI, TAIWAN – Syncore Biotechnology Co. Ltd. (subsidiary of Taipei-based Sinpharm Pharmaceutical Group) received approval from the FDA for its solid tumor oncology agent SB01 to begin a phase II trial for head and neck cancer.